Skymark Research Initiates Independent Research Coverage on Insmed, Inc.
03 Mars 2010 - 7:15AM
Skymark Research, a leading provider of small- and micro-cap
independent investment research, today initiated coverage on
Insmed, Inc. (Nasdaq:INSM)
Skymark Research is currently offering a complimentary trial
subscription. To view our research go to:
www.skymarkresearch.com
About SMR:
Skymark Research is a leading provider of independent investment
research in North America. Our services include research analysis
on the small- and micro-cap markets, real-time news and financial
data, market commentary and the SMR newsletter. Skymark Research's
staff of small-cap investment professionals is dedicated to
providing the small market's investment community with the tools
and avenues necessary to make the important investment decisions.
To view our research reports on a complimentary trial basis and
take advantage of our other services, go to www.skymarkresearch.com
and click on the complimentary trial subscription button on our
home page, or go directly to our registration page at
www.skymarkresearch.com/signup.php
The Skymark Research logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6683
About Insmed, Inc. (Nasdaq:INSM)
Insmed, Inc. (Nasdaq:INSM) is a development stage
biopharmaceutical company specializing in recombinant protein drug
development.
SMR Disclosure:
Skymarkresearch.com is not a registered investment advisor and
nothing contained in any materials should be construed as a
recommendation to buy or sell any securities. Skymark Research has
not been compensated by any of the above mentioned companies.
Please read our report and visit our Web site,
www.skymarkresearch.com, for complete risks and disclosures.
CONTACT: Skymark Research
Dylan Boyle
480-626-1911
info@skymarkresearch.com
![Skymark Research](http://media.primezone.com/cache/11694/small/7418.jpg)
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024